The global Human Growth Hormone Market size was valued at USD 4.76 billion in 2021. It is projected to reach USD 9.36 billion by 2030, growing at a CAGR of 7.80% during the forecast period (2022-2030).
Somatotropin, or human growth hormone, is a peptide hormone generated by the pituitary gland that controls cell development, regeneration and repair, reproduction, and metabolism, all of which are necessary for total human growth. Growth hormone levels in the human body should be adequate for proper growth and can be influenced by physical activity, sleep quality, stress, and low blood sugar levels. Human growth hormones are also involved in bodily fluid balance, sugar and fat metabolism, bone and muscle growth, and injury healing. It also enhances the performance and strength of the muscles.
|Market Size||9.36 billion|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
Growing Investments in R&D
A strong product pipeline and significant R&D expenditures for creating innovative growth hormone therapies are anticipated to drive the market over the forecast period. For instance, Pfizer, Inc. and OPKO Health, Inc. added more information to their Biologics License Application for the investigational medication, somatropin, to treat growth hormone insufficiency in the U.S. FDA in October 2021. Similar to this, several important players are engaged in R&D operations to create innovative HGH medicines, including Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and L.G. Life Sciences.
Market participants are spending money on HGH therapy delivery and monitoring to increase its efficacy and scope for future improvements. For instance, Merck KGaA and Biocorp worked together to create and supply a particular Mallya device version to track the therapy of HGH diseases in September 2021. In order to provide a better product experience, the business chose the remote patient monitoring technology from PRA Health Sciences in April 2021. Investments from significant market participants will fuel the expansion to enhance the quality of life for patients with hormone abnormalities.
Hormone Therapies-Related Side Effects
According to Harvard Health Publishing, many human growth hormone users may encounter adverse effects. Carpal tunnel syndrome, joint pain, soft tissue swelling, edema, and an increase in blood sugar levels can all be brought on by long-term HGH use. Excessive HGH output results in conditions like acromegaly, which aggravates diabetes, arthritis, and high blood pressure. At the beginning of treatment, side effects are frequently more severe in female patients. The adverse effects may vary depending on the hormone therapy utilized. Tiredness, digestive issues, menopausal symptoms, hair thinning, headaches, and blood clots are a few side effects that frequently affect female patients.
Water retention brought on by synthetic growth hormones can result in severe swelling of the limbs, skin sores, and wounds. Additionally, in some circumstances, the system may be exposed to synthetic growth hormones, which may cause the bone-growing process to restart painfully. One such disorder that causes the hands, feet, jaws, and brow ridges to expand is acromegaly. Growth hormone side effects could include gynecomastia and HGH stomach. While gynecomastia is the excessive development of male breasts, the HGH gut is the enlargement of internal organs.
Rising Public Awareness of Growth Hormone Deficiency
Growing public awareness of growth hormone insufficiency and other related illnesses is anticipated to fuel market expansion. Organizations within and outside of government, including the National Organization for Rare Disorders, the Child Growth Foundation, the Pituitary Foundation, the MAGIC Foundation, and the Turner Syndrome Foundation, are constantly working to increase awareness of growth hormone deficiency in different parts of the world. For instance, the Child Growth Foundation is a non-governmental group headquartered in the U.K. that supports individuals with uncommon growth hormone abnormalities.
This group offers information and support to patients, carers, and medical professionals to enhance patients' quality of life. Additionally, these groups improve public awareness of these disorders and support research projects to deepen medical understanding. Every year on September 20, International Child Growth Knowledge Day seeks to raise public and professional awareness of children's growth and the value of comprehending the child growth rate. International groups collaborate to raise awareness of children's development. In many nations, the second or third week of September is also Children's Growth Awareness Week.
The global human growth hormone market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America Dominates the Global Market
North America is the most significant global human growth hormone market shareholder and is expected to grow at a CAGR of 12.50% over the forecast period. Due to excellent reimbursement conditions, an established healthcare infrastructure, considerable government initiatives, and rising healthcare awareness, North America is predicted to make up the most significant portion of the market. The presence of major firms in the area also facilitates greater access to innovative medications, which benefits the North American market. Several significant companies with U.S. headquarters, including Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., provide a variety of human G.H. medicines in the region.
According to the American Academy of Pediatrics, growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the United States. The treatment of chronic renal failure, growth hormone deficiency (GHD), gestational age or intrauterine growth retardation, Turner's syndrome, Prader-Willi syndrome, and cachexia in the U.S. has been made possible by the widespread availability of recombinant growth hormone. Additionally, growing public awareness of growth hormone deficiency and its treatment is anticipated to accelerate market expansion. For instance, to raise awareness about the early detection and treatment of growth hormone disorders, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) observes Children's Growth Awareness Day each year.
Asia-Pacific is anticipated to grow at a CAGR of 10.3% over the forecast period. By obtaining clearance and launching innovative products, a significant market share in potential Asia-Pacific nations like China and Japan is a goal for major firms. For instance, the phase III clinical trial of the pharmaceutical company Novo Nordisk A/HGH S's somapacitan, which is indicated for treating adult growth hormone insufficiency, was started in Japan in March 2017. Due to their large populations, China and India will likely grow into important opportunistic nations for healthcare in the coming years. As a result, pharmaceutical companies, including those that sell HGH medications, are making significant investments in these countries. Recombinant DNA technology is used in the development and production of numerous medicines. These medications primarily treat growth hormone deficiency in adults and children.
The global human growth hormone market is segmented by product, application, and distribution channel.
Based on product, the global market is bifurcated into short-acting growth hormones and long-acting growth hormones.
The short-acting growth hormones segment is the highest contributor to the market and is anticipated to grow at a CAGR of 18.60% over the forecast period. The standard of care for growth hormone shortage for a very long time has been the daily administration of short-acting growth hormones. Due to the rising prevalence of growth hormone deficiency and the availability of numerous products, including Saizen (Merck & Co. Inc.), Humatrope (Eli Lilly & Co.), Genotropin (Pfizer Inc.), and Norditropin (Novo Nordisk A/S), among others, the market for this segment is predicted to grow significantly over the forecast period. These short-acting growth hormone therapies have received approval for reasons like growth hormone deficit, turner syndrome, idiopathic short stature, and small for gestational age. Because these items have been available since 1985, the market is already saturated. Additionally, the major players are making smart moves to enter the industry.
The new growth hormone class, long-acting growth hormones, offers less frequent administration, better patient compliance, and convenience. Due to new launches in key markets and a strong product pipeline, the segment is predicted to increase quickly throughout the projection period. Ascendis Pharma A/S reported in January 2022 that SKYTROFA had received E.C. approval for marketing authorization as a therapy for growth failure in children and adolescents aged 3 to 18. Key players are also working on creating unique long-acting products. For instance, Ngenla is being developed by Pfizer, Inc. and OPKO Health, Inc. In addition, Pfizer received a favorable CHMP opinion from EMA in December 2021, allowing them to commercialize their product in the E.U. to treat growth hormone insufficiency in children and adolescents.
Based on application, the global market is bifurcated into growth hormone deficiency, turner syndrome, idiopathic short stature, Prader-Willi syndrome, small for gestational age, and others.
The growth hormone deficiency segment owns the highest market share and is anticipated to grow at a CAGR of 13.50% over the forecast period. Even though growth hormone insufficiency causes low stature, the issue was not recognized until the early 1900s. Insufficient production of human growth hormone is mainly brought on by pituitary gland malfunction. In 1985, synthetic growth hormones were first made available. The pituitary gland's activity is regulated and stimulated by these recombinant growth hormones. According to research, one in every 3,500 children was found to have a growth hormone deficit. Physiological performance is typically decreased in older persons with HGH deficits. It interferes with lipid metabolism, raises visceral fat, decreases muscle mass and bone density, and generally lowers the quality of life.
Adult growth hormone deficiency is brought on by insufficient anterior pituitary gland growth hormone production. This may be caused by a pituitary tumor, radiotherapy, a severe head injury, an inflammatory condition, or an obstruction of the pituitary gland's blood supply. These hormones have overall metabolic effects and enhance physical and mental performance. Additionally, the launch of novel long-acting growth hormones and the development of new products could accelerate market expansion due to greater usage and shows the advantages of once-weekly administration. For instance, Hanmi Pharm is developing Efpegsomatropin. Co., Ltd. to treat people who lack growth hormones. Clinical trials for efpegsomatropin are currently in phase 2.
The pituitary gland's lack of growth hormone production during childhood leads to pediatric growth hormone insufficiency. With early diagnosis and treatment, children typically reach relatively standard heights and levels of development. Blood transports growth hormones throughout the body to carry out intricate processes, chief among them growth in youngsters. Although pediatric growth hormone insufficiency can be acquired or genetic, most instances still have no recognized etiology.
Based on distribution channels, the global market is bifurcated into hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.
The hospital pharmacies segment is the highest contributor to the market and is anticipated to grow at a CAGR of 14.00% over the forecast period. Due to increased patient visits, follow-ups, and diagnoses of growth hormone insufficiency, the hospital pharmacy market is predicted to experience significant growth throughout the projection period. In the United States, during the variable follow-up period, about 4,308 (63.2%) Medicaid patients and 9,625 (68.4%) commercial patients with growth hormone deficiency received somatropin treatment, while 36.8% of Medicaid and 31.6% of commercial patients went untreated, according to Journal of Managed Care. In addition, Medicaid patients received 41.5 treated patients for every 100 person-years, compared to 55.4 treated patients for commercial patients.
The extensive availability of major drugstore chains, including Walgreens, Walmart, CVS Caremark, and others, and other reasons, suggest that the retail pharmacy industry will grow throughout the projected period. However, retail pharmacies are permitted to fill prescriptions for around 30 days. The retail pharmacy service more conveniently meets short-term prescription needs. Genotropin, Norditropin, Omnitrope, Saizen, and Zomacton, among other medications, are exclusively covered by pharmacy benefit programs, according to Blue Cross Blue Shield Association.
The segment for internet pharmacies is anticipated to increase at the fastest rate over the forecast period. The online pharmacy platform promotes safety and social seclusion. Due to the comfort, flexibility, and convenience that the platform provides, the trend of online shopping is expanding. This is boosting the category and resulting in significant sales. Additionally, clients can benefit from various discounts offered by online purchasing. These factors are anticipated to fuel demand for online pharmacies.
The global human growth hormone market's major companies are